User profiles for "author:Alain Ravaud"
Alain RavaudBordeaux Verified email at chu-bordeaux.fr Cited by 47346 |
[HTML][HTML] Immune checkpoint inhibitors and elderly people: a review
A Daste, C Domblides, M Gross-Goupil… - European Journal of …, 2017 - Elsevier
Immune checkpoint inhibitors, including targeting programmed cell death 1, programmed
cell death ligand 1, and cytotoxic T lymphocyte antigen 4 pathways, are a new type of cancer …
cell death ligand 1, and cytotoxic T lymphocyte antigen 4 pathways, are a new type of cancer …
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
PURPOSE: In April 2009, an expert group of 11 physicians and clinical nurses met to
discuss the management of selected adverse events associated with the use of everolimus …
discuss the management of selected adverse events associated with the use of everolimus …
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers
PURPOSE: Metastasis remains the main cause of death in both bladder (BCa) and prostate
(PCa) cancers. The results of chemotherapy did not show any significant improvement of the …
(PCa) cancers. The results of chemotherapy did not show any significant improvement of the …
[HTML][HTML] Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …
with encouraging overall survival in uncontrolled studies involving previously treated …
[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian
target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did …
target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did …
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
B Escudier, A Pluzanska, P Koralewski, A Ravaud… - The Lancet, 2007 - thelancet.com
Background Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic
approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of …
approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of …
[HTML][HTML] Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
S Negrier, B Escudier, C Lasset… - … England Journal of …, 1998 - Mass Medical Soc
Background Recombinant human interleukin-2 (aldesleukin) and recombinant human
interferon alfa can induce notable tumor regression in a limited number of patients with …
interferon alfa can induce notable tumor regression in a limited number of patients with …
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label …
Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the …
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the …